Cannabis stocks surge as Trump consider reclassifying the drug

Cannabis stocks surged significantly, with Trulieve up 35% and Tilray 32%, following reports that President Trump is considering reclassifying marijuana from Schedule I to Schedule III. This potential move, which Trump confirmed his administration is "looking at" for a determination in the coming weeks, would critically enable cannabis businesses to claim normal tax deductions, facilitate medical research, and improve banking access, fundamentally altering the industry's operating environment.

Analysis

The cannabis sector is experiencing a significant, sentiment-driven rally following reports that the Trump administration is considering rescheduling marijuana from a Schedule I to a Schedule III drug. This potential regulatory shift has catalyzed sharp upward movements in key stocks, with Trulieve Cannabis Corp. surging 35%, Tilray Inc. up 32%, and Curaleaf Hldgs Inc. adding 29%. The core of this bullish reaction lies in the profound operational and financial benefits such a reclassification would unlock. Specifically, it would permit cannabis businesses to claim normal business tax deductions and credits, directly addressing a major impediment to profitability. Furthermore, the move would facilitate improved access to banking services and expand medical research, tackling fundamental structural challenges that have long hindered the industry's growth and access to institutional capital. With a determination from the administration expected in the "coming weeks," the market is pricing in a substantially de-risked and more viable operating environment.

Key Decisions for Investors

• Investors should recognize that the recent surge is event-driven and monitor White House communications closely, as the stocks' performance is highly contingent on the binary outcome of the reclassification decision.
• Given the sharp, double-digit gains, it may be prudent to consider trimming positions to lock in some profits, or to implement hedging strategies to protect against the downside risk of a negative or delayed announcement.
• Consider the potential for differentiated impact across the sector, as U.S. multi-state operators would be the primary beneficiaries of the tax relief component of a Schedule III reclassification.